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Abstract
Background: Polymorphisms in glutathione S-transferase (GST) genes may influence response to
oxidative stress and modify prostate cancer (PCA) susceptibility. These enzymes generally detoxify
endogenous and exogenous agents, but also participate in the activation and inactivation of
oxidative metabolites that may contribute to PCA development. Genetic variations within selected
GST genes may influence PCA risk following exposure to carcinogen compounds found in cigarette
smoke and decreased the ability to detoxify them. Thus, we evaluated the effects of polymorphic
GSTs (M1, T1, and P1) alone and combined with cigarette smoking on PCA susceptibility.
Methods: In order to evaluate the effects of GST polymorphisms in relation to PCA risk, we used
TaqMan allelic discrimination assays along with a multi-faceted statistical strategy involving
conventional and advanced statistical methodologies (e.g., Multifactor Dimensionality Reduction
and Interaction Graphs). Genetic profiles collected from 873 men of African-descent (208 cases
and 665 controls) were utilized to systematically evaluate the single and joint modifying effects of
GSTM1 and GSTT1 gene deletions, GSTP1 105 Val and cigarette smoking on PCA risk.
Results: We observed a moderately significant association between risk among men possessing at
least one variant GSTP1 105 Val allele (OR = 1.56; 95%CI = 0.95-2.58; p = 0.049), which was
confirmed by MDR permutation testing (p = 0.001). We did not observe any significant single gene
effects among GSTM1 (OR = 1.08; 95%CI = 0.65-1.82; p = 0.718) and GSTT1 (OR = 1.15; 95%CI =
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0.66-2.02; p = 0.622) on PCA risk among all subjects. Although the GSTM1-GSTP1  pairwise
combination was selected as the best two factor LR and MDR models (p = 0.01), assessment of the
hierarchical entropy graph suggested that the observed synergistic effect was primarily driven by
the GSTP1 Val marker. Notably, the GSTM1-GSTP1 axis did not provide additional information gain
when compared to either loci alone based on a hierarchical entropy algorithm and graph. Smoking
status did not significantly modify the relationship between the GST SNPs and PCA.
Conclusion: A moderately significant association was observed between PCA risk and men
possessing at least one variant GSTP1 105 Val allele (p = 0.049) among men of African descent. We
also observed a 2.1-fold increase in PCA risk associated with men possessing the GSTP1 (Val/Val)
and GSTM1 (*1/*1 + *1/*0) alleles. MDR analysis validated these findings; detecting GSTP1 105 Val
(p = 0.001) as the best single factor for predicting PCA risk. Our findings emphasize the importance
of utilizing a combination of traditional and advanced statistical tools to identify and validate single
gene and multi-locus interactions in relation to cancer susceptibility.
Background
Even though prostate cancer (PCA) ranks the highest in
incidence and second mortality among all cancers affect-
ing American men, its etiology and ethnic disparities are
largely unknown[1]. For instance, age and family history
are the strongest risk factors for PCA, but African-Ameri-
can (AA) men are more than twice as likely to develop the
disease compared to other racial or ethnic groups[1]. AA
men are also more likely to be diagnosed with PCA at a
younger age, with more aggressive disease and poorer
prognosis [1-3]. Despite increases in five year survival
rates for AA men over the last few decades; their rates still
lag far behind other races[1]. While, the reasons for this
disparity are largely speculative; risk, incidence, and mor-
tality rates suggest that genetic factors play an important
role in PCA initiation and progression[1]. However, life-
style habits (e.g., cigarette smoking, diet) have also been
implicated to increase risk; indicating that environmental
factors may contribute to PCA[1,2,4]. Therefore, prostate
carcinogenesis and its disparity most likely involve a com-
plex interplay between genetic and environmental factors.
More specifically, variations in carcinogen metabolism
genes may play a critical role in PCA development due to
their activation or detoxification functions.
The  glutathione S-transferase (GST) gene superfamily
encodes enzymes that catalyze the conjugation of glutath-
ione to electrophilic compounds[5,6]. These enzymes
generally detoxify endogenous and exogenous agents, but
also participate in the activation and inactivation of oxi-
dative metabolites of carcinogenic compounds associated
with prostate cancer[7,8]. Variant GST alleles have been
identified within the general population. The most exten-
sively studied variant GSTs include two GST deletion alle-
les (i.e., GSTM1*0/*0 [GenBank: BC024005.2] and
GSTT1*0/*0 [GenBank: BC007065.1]) and the GSTP1 Val
allele which is characterized by an adenine to guanine
substitution at position -313 (A-313G) in exon 5 [Gen-
Bank: BC010915.1; dbSNP: rs1695][9]. The functional
consequences of the GSTM1 and GSTT1 (*0/*0) geno-
types are obvious in terms of enzyme activity; gene dele-
tion results in loss of conjugation potential. The GSTP1
polymorphism, resulting from an isoleucine to valine
substitution within the active site of the enzyme at codon
105 (I105V), is linked to altered substrate-specific ther-
mostability and conjugation activity [10-12]. For instance,
the GSTP1 105 Val variant has been associated with lower
efficiency for diol epoxides of some polycyclic aromatic
hydrocarbons, therefore resulting in decreased detoxifica-
tion of these compounds compared to the Ile allele[10].
Genetic variations in polymorphic GST genes have been
implicated in the etiology of numerous cancers [13-18].
Some studies indicate GST polymorphisms are associated
with prostate cancer; however, this association is not
accepted across all observational studies [18-25]. Discrep-
ancies may be partially attributed to failure to consider
gene combinations or interactions with tobacco smoking.
Furthermore, few studies have involved a sufficient
number of African-Americans in order to adequately
investigate the role of GST polymorphisms and environ-
mental factors in PCA development[12,26,27].
To clarify the role of GST genes in PCA risk within a high-
risk sub-group, we evaluated the individual and joint
modifying effects of three commonly studied sequence
variants in a case-control study of 208 cases and 665 dis-
ease-free controls among a population of men of African
descent. In an exploratory analysis, we evaluated gene-
gene interactions using an available non-parametric statis-
tical model, namely Multifactor Dimensionality Reduc-
tion (MDR). This advanced statistical tool readily
overcomes sample size limitations often encountered by
parametric statistical methods (e.g., logistic regression
analysis). MDR has greater than 80% statistical power and
rigor to evaluate gene-gene interactions even in the pres-
ence of small sample sizes (i.e., 200 cases and 200 con-
trols). This computationally sound statistical tool enabledBMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
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evaluations of single and multi-locus genetic and environ-
mental markers as indicators of PCA susceptibility within
our population sample.
Methods
Study population
Unrelated male residents (n = 1016) of Washington D.C.
and Columbia SC, were considered for eligibility in the
current PCA case control study. Study participants (n =
132) were not considered in the current study if they met
one or more of the following exclusion criteria: (1) they
were diagnosed with benign prostatic hyperplasia (n =
64); (2) had an abnormal prostate specific antigen (PSA)
and digital rectal examination (DRE) (n = 11); and (3)
had European ancestry based on a Global Ancestry score
of < 25% (n = 70)[28]. Eligible men of African descent
(i.e., self-identified African-Americans, East Africans, West
Africans, and Afro-Caribbeans), including 208 patients
(ages 41-91) and 665 healthy volunteers (ages 26-89),
were recruited from the Howard University Hospital
(HUH) Division of Urology PCA patient population, the
HUH PCA screening program, and the South Carolina
PCA screening program (Table 1). The PCA patients and
screening participants, recruited between 2001 and 2005,
had a PSA and DRE. Subjects who had an abnormal PSA
(>4.0 ng/ml) and/or irregular DRE underwent multiple
core needle biopsies. Incident PCA cases in the current
study were identified by an HUH urologist based on
abnormal PSA (>2.5 ng/ml) and/or DRE as well as histo-
logical findings following a radical prostatectomy. Inclu-
sion criteria of controls were men with PSA levels ≤ 2.5 ng/
ml and/or normal DREs/biopsies. Tumor grade, ranging
from 4-10, was collected for 62.0% of the cases (n = 129).
Subjects (n = 216) were classified as current (n = 38),
former (n = 71) and never (n = 107) smokers. All study
participants had available DNA extracted from whole
blood and provided written informed consent for partici-
pation in genetic analysis studies under a protocol
approved by the Howard University Institutional Review
Board as well as from the HUH Division of Urology.
Table 1: Patient and Tumor Characteristics
Characteristics Cases Controls p-valuea
Number of Participants, n 208 665 ---
Age (yrs)
Median (range) 65 (41-91) 52 (26-89) 0.0001
PSA in ng/ml n (%)
< 4 43 (22.0) 609 (94.4) < 0.0001
≥ 4 152 (78.0) 36 (5.6)
Gleason Score n (%)
41 7  ( 1 3 . 2 )
51 5  ( 1 1 . 6 )
63 3  ( 2 5 . 6 )
74 0  ( 3 1 . 0 )
8 6 (4.6)
91 4  ( 1 0 . 9 )
10 4 (3.10)
Smokers n (%)
Never 62 (45.6) 45 (20.8) 0.162
Former 51 (37.5) 20 (25.0)
Current 23 (16.9) 15 (18.8)
Eversmokers n (%)
No 62 (45.6) 45 (56.3) 0.130
Yes 74 (54.4) 35 (43.8)
Global West African Ancestry
Median (SD)
0.791 (0.253-0.947) 0.718 (0.255-0.946) 0.020
Abbreviations: PSA, prostate specific antigen
aDifferences in frequencies were tested by a Chi-square test of heterogeneity (i.e., PSA ng/ml); Differences in age and Global West African Ancestry 
between cases and controls were tested using the Wilcoxon sum Rank test.BMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
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TaqMan allelic discrimination of GSTM1, GSTP1 and 
GSTT1 sequence variants
Polymorphisms in three glutathione S-transferases genes
were ascertained using TaqMan Polymerase Chain Reac-
tion (PCR) allelic discrimination assays. The following
alleles were detected: (1) GSTM1 (*1/*1 + *1/*0); (2)
GSTT1 (*1/*0 + *1/*0); and (3) GSTP1 (Ile105Val). The
albumin reference gene served as a positive control for
GST (M1, T1) deletions. The discrimination assay con-
tained approximately 40 ng of germ-line DNA, 1× Univer-
sal Master Mix (Applied Biosystems), 900 nM of each
primer (forward and reverse), and 400 nM of each probe
(FAM and VIC) to comprise a 10 μl reaction. The primers
and probes used to detect a deletion or single nucleotide
polymorphisms (SNP) detected in GSTM1, GSTP1  and
GSTT1 alleles were obtained using the NCI SNP500 data-
base, published reports and Primer Express 3.0 software
(Applied Biosystems, Foster City, CA) [29-31]. The PCR
amplification conditions consisted of the following: an
initial 2 step hold (50°C for 2 min, followed by 95°C for
10 min) and 40 cycles of a two-step PCR (95°C for 15 s,
60°C for 1 min)[30]. The fluorescent intensity emitted
from the fluorogenic probes were measured using the ABI
7900HT sequence detection system and assigned geno-
types using SDS 2.2.1 software (Applied Biosystems, Fos-
ter City, CA). To minimize misclassification bias,
laboratory technicians were blinded to the case status of
study participants. Based on 24 non-DNA template con-
trols per batch analysis, percent cross-contamination dur-
ing sample handling was negligent (<0%). Duplicate
genotyping performed on 72 randomly selected samples
for quality control purposes resulted in concordance rates
of 96-97% for GST (M1, T1) and 100% for GSTP1. Call
rates were >94% for the GST deletion (M1, T1) and GSTP1
allelic discrimination assays. In addition, we tested
whether the aforementioned GST polymorphisms were in
Hardy-Weinberg equilibrium among controls using a sig-
nificance level of p < 0.05.
Ancestry markers
One hundred previously validated autosomal ancestry
markers were included to account for potential popula-
tion stratification among our admixed population of self-
reported African-Americans, West African, East African,
Afro-Caribbean, as previously described[32]. Study partic-
ipants were grouped from lowest to highest genetic West
African Ancestry (WAA), with scores ranging from 0-
100%. These 100 markers were assembled using DNA
from self-identified African-Americans (Coriell Institute
for Medical Research, n = 96), Yoruban West Africans
(HapMap, n = 60), West Africans (Bantu and Nilo Saharan
speakers, n = 72), Europeans (New York City, n = 24), and
CEPH Europeans (HapMap Panel, n = 60), as previously
reported[32]. Individuals (n = 873) with a high degree of
WAA greater than or equal to 25% were considered in the
final analysis.
Evaluation of individual GST loci and PCA risk using LR 
analysis
To assess whether inheritance of at least one GST (M1, T1)
deletion or GSTP1 Val allele was associated with elevated
risk of developing PCA, we tested for significant differ-
ences in the distribution of variant genotypes between
208 cases and 665 controls using the chi-square test of
homogeneity. Associations between PCA risk and candi-
date polymorphic genes, expressed as odds ratios (ORs)
and corresponding 95% confidence intervals (CIs), were
estimated using unconditional multivariate logistic
regression (LR) models adjusted for potential confound-
ers [age (yrs), PSA (ng/ml), and WAA (continuous)]. All
reported risk estimates and 95% CIs for the selected poly-
morphic GST genes used the following as reference geno-
types: GSTM1 (*1/*1 + *1/*0), GSTT1 (*1/*1 + *1/*0),
GSTP1 (Ile/Ile). Test for trend included genotypes as ordi-
nal variables. Statistical significance was assessed using a
p-value < 0.05. All chi-square test and LR analyses were
conducted using SAS 9.1.3 (SAS Institute, Cary, NC).
Gene combination effects
MDR was used to evaluate gene-gene interactions associ-
ated with PCA risk. This tool aids in the identification of
high-risk markers using a cross validation strategy to esti-
mate the classification and prediction accuracy of individ-
ual and multifactor models [33-35]. MDR is a data mining
platform that readily overcomes sample size limitations
often encountered by parametric statistical methods (e.g.,
LR analysis) by collapsing high-dimensional genetic data
into a single dimension [33-35]. Also, MDR is a "model-
free" (it does not assume a specified genetic model) and
"non-parametric" method (it does not estimate parame-
ters) that is effective with relatively small sample sizes [33-
35]. With MDR, we pooled multi-locus factors into high-
risk and low-risk groups, thereby reducing the otherwise
high-dimensional data to a single variable and permitting
an investigation of individual GST genes, gene combina-
tion effects, and GST-tobacco smoking interactions. This
one-dimensional multi-locus variable was evaluated for
its ability to classify and predict PCA susceptibility
through cross-validation and permutation testing. MDR
was utilized to generate a single model that maximizes the
number of individuals with the proper risk assignment.
Single best factor models were selected among each of the
one- or two- factor combinations based on those that
minimize the prediction error as well as maximize cross
validation consistency (CVC) and average testing accuracy
(ATA). To evaluate the number of times the same individ-
ual loci or set of genes was identified in each possible 9/
10ths of the data, the average CVC (based on a scale from
0-100%) from the observed data was compared to the dis-BMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
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tribution of average consistencies under the null hypoth-
esis of no association. Statistically significant single and
multi-locus models may be adjusted for potential con-
founders by placing the MDR output variables into a LR
model. Furthermore, validation of models as effective pre-
dictors of prostate cancer susceptibility was derived
empirically from 1,000 permutations. This approach
accounted for multiple testing issues as long as the entire
model fitting procedure was repeated for each rand-
omized dataset to provide an opportunity to identify
false-positives. We considered MDR permutation results
to be statistically significant at the 0.05 level. LR analysis
was used to perform two-way interaction models for risk
estimates terms identified by MDR.
Interaction Entropy Graphs
Interaction entropy was used as a third strategy to verify,
visualize, and interpret combination effects identified by
LR and MDR [36,37]. Interaction entropy uses informa-
tion gain (IG) to gauge whether interactions between two
or more variables provide more information about a class
variable relative to each variable considered independ-
ently [36] and has been applied to several recent epidemi-
ological studies [34,36,38,39]. The colors range from red
representing a high degree of synergy (positive informa-
tion gain), orange a lesser degree, and gold representing
independence and a midway point between synergy and
redundancy. Blue represents the highest level of redun-
dancy (negative information gain), followed by green.
Results
The patient and tumor characteristics in the current study
are summarized in Table 1. Cases were significantly older
than controls and had higher PSA levels. Although there
was a small portion of controls (5.6%) who had PSA lev-
els that exceeded 4.0 ng/ml, these individuals did not
have an abnormal DRE or irregular biopsy. There was a
significant difference in median West African genetic
ancestry estimates comparing cases and controls (p =
0.020). Cigarette smoking data was available for approxi-
mately 25% of our study subjects (n = 216, 136 cases and
80 controls). These subjects were classified by cigarette
smoking: current (n = 38), former (n = 71) and never (n =
107). Cigarette smoking did not differ significantly (p >
0.05) between cases and controls.
Within our study set, inheritance of two GST (M1, T1)
deletions or at least one GSTP1 105 Val allele was fairly
common among controls with frequencies ranging from
17.5-47.9%, as detailed in Table 2. The genotype frequen-
cies among controls were comparable to those observed
in other African descendent sub-groups[26,40,41]. The
genotype frequencies among controls did not deviate
from expected distributions based on the Hardy-Weinberg
equilibrium (p ≥ 0.138).
We evaluated the independent effects of genetic variations
in highly variant GST genes in relation to PCA susceptibil-
ity using unconditional LR models, as detailed in Table 2.
Inheritance of at least one GSTP1 105 Val allele (linked
with decreased capacity to conjugate electrophilic com-
pounds) was associated with a 1.6-fold increase in pros-
tate cancer risk (OR = 1.56; 95%CI = 0.95-2.58; p =
0.049). The GSTP1 Val loci was also identified as the best
single factor predictor of PCA based on a cross-validation
consistency of 100%, an average testing accuracy of 53%
Table 2: Association between prostate cancer risk and selected GST gene variations
Gene SNP Case
n (%)
Control
n (%)
Risk Estimate†
OR (95% CI)
Risk Estimate††
Adj OR (95% CI)
p-value††† p-value for Trend
GSTP1 AA (Ile/Ile) 55 (29.0) 186 (32.5) 1.00 (Reference) 1.00 (Reference)
A313G AG (Ile/Val) 85 (44.7) 274 (47.9) 1.12 (0.77-1.63) 1.09 (0.67-1.81)
Ile105Val GG(Val/Val) 50 (26.3) 112 (19.6) 1.62 (1.04-2.51) 1.66 (0.94-2.96) 0.141 0.080
AG+GG 140 (73.7) 460 (80.4) 1.47 (1.00-2.15) 1.56 (0.95-2.58) 0.049
missing 6 (3.2) 35 (6.1)
GSTM1 *1/*1 + *1/*0 141 (75.0) 441 (76.3) 1.00 (Reference) 1.00 (Reference)
Deletion *0/*0 47 (25.0) 137 (23.7) 1.07 (0.73-15.7) 1.08 (0.65-1.82) 0.718
missing 8 (4.3) 29 (5.0)
GSTT1 *1/*1 + *1/*0 153 (81.0) 482 (82.5) 1.00 (Reference) 1.00 (Reference)
Deletion *0/*0 36 (19.0) 102 (17.5) 1.11 (0.73-1.69) 1.15 (0.66-2.02) 0.622
missing 7 (3.7) 23 (3.9)
†Associations were determined using multivariate logistic regression models to estimate the risk of developing PCA using GSTP1 105 Ile/Ile, GSTM1 
*1/*1 + *1/*0 and GSTT1 *1/*1 + *1/*0 as the reference genotypes.
††Risk estimates adjusted for age (continuous variable); prostate specific antigen (continuous variable); and West African Ancestry, WAA or 
admixture (continuous variable).
†††Differences in the frequency of high-risk and low-risk genotypes between cases and controls were determined using the chi-square test of 
association with a significance level of 0.05.BMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
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and a 1000-fold permutation testing p-value of 0.001
(Table 3). Upon evaluation of gene-gene combination
effects, LR modeling revealed a 2.1-fold increase in PCA
risk associated with men possessing the GSTP1 (Val/Val)
and GSTM1 (*1/*1 + *1/*0) alleles (OR = 2.11; 95%CI =
1.07-4.16; p-value for interaction = 0.062). Initially, it
appeared as though this interaction was a significant PCA
predictor following MDR analysis with a statistically sig-
nificant 1000-fold permutation testing p-value of 0.01.
However, this gene combination effect was primarily
driven by the GSTP1 loci attributed to the lack of addi-
tional information gain comparing the GSTM1-GSTP1
axis (IG = 0.04%) to either GSTP1 or GSTM1 loci alone
(IG = 0.58% and 0.03%, respectively) (Figure 1). Lastly,
no significant risk effects were detected among the GST
deletion polymorphisms (p = 0.622) or the GSTP1-GSTP1
and GSTM1-GSTT1 combinations (p = 0.557 and 0.814,
respectively). For our exploratory analysis of gene-envi-
ronment interactions associated with risk, LR modeling
indicated that smoking status did not modify the relation-
ship between the GST SNPs and PCA risk (p for interac-
tion ≥ 0.135), as shown in Table 4.
Discussion
Previous studies suggest that oxidative stress and reactive
species are becoming increasingly important in prostate
carcinogenesis[4,11,12,42-45]. If these electrophilic com-
pounds are not removed or reduced to less active forms,
they may result in damage to biomolecules (e.g., DNA,
proteins, etc.) and ultimately lead to cellular dysfunction
or transformation. Consequently, the role of antioxidant
enzymes has been commonly investigated in relation to
PCA development because of their function in the detoxi-
fication of potentially damaging carcinogens and/or reac-
tive oxygen species (ROS)[4,46-48]. The GSTs  in
particular have been extensively studied since they are
able to conjugate a wide range of oxidative sub-
strates[6,11,43,49,50]. Variations within these genes can
cause a loss or reduction in enzymatic activity and have
been associated with increased risk of prostate as well as
several other cancers (e.g., colon, breast, and
lung)[6,12,51-53].
In the case of PCA, reports have observed that PCA cases
possess lower antioxidant enzyme levels in prostate tis-
sues compared to both healthy controls and men with
benign prostatic hyperplasia (BPH)[48]. In addition, PCA
tissues appear to contain higher amounts of ROS and oxi-
dative DNA damage [46-48]. Some investigators speculate
these effects may be attributed to GST genetic polymor-
phisms (i.e., GSTM1*0/*0, GSTT1*0/*0, and GSTP1 Val)
linked with compromised oxidative repair capac-
ity[5,12,26,41,43,54]. The goal of this study was to evalu-
ate GSTM1 and GSTT1 gene deletions, variant GSTP1 105
Val, and cigarette smoking as predictors of PCA risk
among 873 men of African descent (208 cases and 665
controls). We hypothesized that individuals who possess
one or more genotypes associated with reduced detoxifi-
Interaction entropy model for GST gene variations and prostate cancer risk Figure 1
Interaction entropy model for GST gene variations and prostate cancer risk. This graphical model, describes the 
percent entropy that is explained by each GST SNP or a combination of two loci within our study population. Positive percent 
entropy indicates information gain or synergy. However, negative percent indicates redundancy or lack of information gain. 
Schematic coloration used in the visualization tools represents a continuum from synergy (i.e. non-additive) to redundancy. 
The colors range from red representing a high degree of synergy (positive information gain), orange a lesser degree, and gold 
representing independence and a midway point between synergy and redundancy. On the other hand, green represents redun-
dancy. Note that the gene combination effect is primarily driven by the GSTP1 loci attributed to the lack of additional informa-
tion gain comparing the GSTM1-GSTP1 axis (IG = 0.04%) to either GSTP1 or GSTM1 loci alone (IG = 0.58% and 0.03%, 
respectively)BMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
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cation would have a higher risk of developing PCA. In an
exploratory analysis, we investigated the effects of ciga-
rette smoking combined with these polymorphisms in
relation to PCA risk. This increased risk may be partially
attributed to exposure to tobacco carcinogens and altered
capacity to metabolically detoxify hazardous compounds.
Logistic regression analysis revealed a moderately signifi-
cant association between PCA susceptibility and GSTP1
105 Val. These findings were confirmed using a robust
data-mining tool specifically designed to evaluate main
effects and higher order interactions. Although we did not
detect any significant single gene effects among GSTM1
and T1 deletions, we did observe a moderately synergistic
interaction between GSTP1-GSTM1 and PCA susceptibil-
ity. We found a 2.1-fold increase in PCA risk associated
with men possessing 2-3 high risk alleles with the GSTP1
GG (Val/Val) &GSTM1 *1/*1 + *1/*0 genotype according
to logistic regression analysis.
Numerous previous studies have investigated the role of
these GST polymorphisms in relation to PCA susceptibil-
ity. For example, Agalliu et al. 2006 reported a moderate
increase in PCA risk associated with the GSTM1 gene dele-
tion for Caucasian men (OR = 1.54; 95%CI = 1.19-2.01);
however, GSTT1 deletion and GSTP1 105 Val polymor-
phisms were not significantly associated with prostate
cancer[5]. The null findings for GSTT1 and GSTP1 were
corroborated in a recent meta-analysis of pooled data
from ≥ 3,837 cases and ≥ 4,552 controls[12]. This same
report, however, observed a 1.3 fold increase in PCA risk
among all study participants was associated with the
GSTM1*0 loci using pooled data from 4,564 cases and
5,464 controls (OR = 1.33; 95%CI = 1.15-1.55)[12]. Strat-
ification based on self-identified race indicated that risk
estimates were comparable between Caucasians and
Asians; however, the GSTM1 and GSTT1 deletion poly-
morphisms did not modify risk among Africans or Afri-
can-Americans[12]. Interestingly, only two published
studies investigated the role of the GSTP1 105 Val SNP in
relation to PCA among men of African descent[5,12,54].
The null findings in these two reports may be partially
attributed to the failure to utilize rigorous statistical tools
that permit the evaluation of main effects even in the pres-
ence of small sample sizes (i.e., at least 200 cases and 200
controls) such as MDR. The MDR selection of the GSTP1
105 Val loci as a significant PCA predictor in the current
study is promising and will undergo subsequent valida-
tion within future studies among men of African descent.
We have considered the strengths and limitations of the
current study. Although MDR doesn't allow for adjust-
ments of covariates, it does control for multiple compari-
Table 3: Multifactor Dimensionality Reduction Models for GST gene variations and prostate cancer risk
Best Model Cross Validation Consistency (CVC) Average Testing Accuracy (ATA) Permutation Testing p-value
One Factor
GSTP1 10/10 0.530 0.001
Two Factor
GSTP1 8/10 0.535 0.01
GSTM1
Table 4: Combined effects of GST polymorphisms and smoking on prostate cancer risk
Gene Polymorphism Adjusted OR (95% CI) for Non-
smokers†‡
Adjusted OR (95% CI) for Ever-
smokers††‡
p-value for Interaction
GSTP1 AA (Ile/Ile) & AG (Ile/Val) 1.00 (Reference) 2.88 (0.49-16.82)
A313G GG (Val/Val) 1.91 (0.47-7.82) 1.42 (0.33-6.10) 0.928
Ile105Val
GSTM1 *1/*1 + *1/*0 1.00 (Reference) 1.71 (0.59-4.97)
Deletion *0/*0 1.61 (0.36-7.28) 0.47 (0.11-2.09) 0.135
GSTT1 *1/*1 + *1/*0 1.00 (Reference) 1.03 (0.37-2.89)
Deletion *0/*0 1.02 (0.21-4.94) 2.12 (0.47-9.57) 0.410
†Associations were determined using multivariate logistic regression models to estimate the risk of developing PCA using GSTP1 105 Ile/Ile, GSTM1 
*1/*1 + *1/*0 and GSTT1 *1/*1 + *1/*0 as the Reference genotypes.
††Risk estimates adjusted for age (continuous variable); prostate specific antigen (continuous variable); and West African Ancestry, WAA or 
admixture (continuous variable).
‡Non-smokers are subjects that have never smoked; Ever-smokers are subjects that are current or former smokersBMC Cancer 2009, 9:397 http://www.biomedcentral.com/1471-2407/9/397
Page 8 of 10
(page number not for citation purposes)
sons and spurious risk estimates by using a cross
validation and permutation testing scheme as a built-in
feature. Misclassification by case status is also a potential
limitation for this study. There is a slight possibility that
some of the controls with PSA less than 4 ng/ml may actu-
ally have prostate cancer that remains undetected. Con-
trols who had an abnormal PSA (>4.0 ng/ml) and/or
irregular DRE underwent multiple core needle biopsies.
Patients with an abnormal biopsy were reclassified as
cases. Participants with a PSA (i.e., ≤ 4.0 ng/ml) but an
abnormal DRE were excluded abnormal DRE were
excluded from participating in the current study. These
individuals were excluded because we could not predict
with any level of certainty whether these individuals
would develop prostate cancer. We also excluded individ-
uals who were: (1) diagnosed with BPH following a
biopsy; or (2) had an abnormal PSA and/or an irregular
DRE. Since one cannot predict with any level of certainty
whether individuals diagnosed with BPH would develop
prostate cancer, these individuals were excluded from the
current study. As implied within Lobe et al., 2006, even
after close inspection of prostate cancer tissue, it is possi-
ble to miss a microscopic nodule that can later develop
into cancer[55]. If controls in our study population were
still misclassified after undergoing a PSA test, DRE, and/or
multiple core needle biopsies, then we may expect our cal-
culated risk estimates to underestimate the relationship
between the selected GST polymorphisms and prostate
cancer susceptibility. But this issue plaques all cancer epi-
demiology studies. Unfortunately, it is impractical to sub-
ject all patients to a radical prostatectomy to permit an
extensive evaluation and more accurate classification of
case status.
Another challenge for genetic epidemiology studies
involving study participants of African descent is their
unique population history of gene flow from divergent
populations[56,57]. The current study adjusted single loci
models for genetic heterogeneity (i.e., population admix-
ture). This also helps to circumvent misclassification of
study participants related to self-identified race/ethnicity
(SIRE). Our findings suggest that inclusion of WAA did
not significantly change the risk estimates relative to
unadjusted models; if anything it makes them more pre-
cise. Also, this study may be limited due to lack of consid-
eration of the genetic heterogeneity of selected targets.
This could be the reason we did not observe any statistical
significant effects among GST polymorphisms and smok-
ing interactions in relation to PCA risk (p = 0.105).
Conclusion
In summary, our findings indicate a moderately signifi-
cant association between risk and among men possessing
at least one variant GSTP1  105 Val allele (p = 0.049)
among men of African descent. MDR analysis validated
the logistic regression findings and identified the
GSTP1105 Val allele (p = 0.001) as the best single factor
model for predicting PCA risk. The ability of MDR to eval-
uate main effects and remain effective with relatively
small sample sizes of at least 200 cases and 200 controls
strengthens the power of this study. Statistically signifi-
cant single and multi-locus models maybe adjusted for
potential confounders by placing the MDR output varia-
bles into a LR model. Furthermore, this study is robust
since it utilizes multiple statistical analysis tools to exam-
ine the single gene as well as gene-gene or gene-cigarette
smoking combination effects in relation to PCA risk.
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